Birmingham, ALNCT05948566Now EnrollingIRB Ready

Ischemic Stroke Clinical Trial in Birmingham, AL

Access cutting-edge ischemic stroke treatment through this phase 2 clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.

Sponsored by Translational Sciences, Inc.

Quick Self-Assessment

See if you qualify for this Birmingham location

Preparing your pre-screening questions…

Expert Care in Birmingham

Access ischemic stroke specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related ischemic stroke treatment provided free

Apply for This Birmingham Location

Check if you qualify for this ischemic stroke clinical trial in Birmingham, AL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Birmingham

    Convenient for AL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Birmingham site if eligible
  4. 4Begin participation

About This Ischemic Stroke Study in Birmingham

SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.

Sponsor: Translational Sciences, Inc.

Who Can Participate

Inclusion Criteria

Age 18 years and older
Suspected anterior circulation acute ischemic stroke
NIH Stroke Scale score ≥4 prior to randomization a. The participant must have a clearly disabling deficit if NIHSS is 4-5.
Favorable baseline neuroimaging consisting of all of the following:
ASPECTS of 6 or more on CT (or ASPECTS of ≥7 on MRI)
Favorable perfusion imaging on CT perfusion (CTP)/MR-perfusion weighted imaging (PWI) consisting of all of the following: i. Mismatch ratio of penumbra: core \>1.2 ii. Mismatch volume \>10 cc iii. Core \<70 cc c. If CT hypodensity is present, then in the investigator's visual assessment, the total acute infarct volume combined area of (a) the CT hypodensity and (b) the perfusion-based core volume (CBF\<30%) should be smaller than perfusion-based volume (area of Tmax\>6s minus CBF\<30%).
Able to receive assigned study drug within 4.5 to 24 hours of stroke onset or last known well.
Able to receive assigned study drug within 120 minutes of qualifying perfusion imaging. \
Informed consent for the study participation obtained from participant or their legally authorized representatives.
Study drug administration is encouraged within 90 minutes after qualifying perfusion image but is allowed up to 120 minutes. After 120 minutes, another perfusion image to ensure that inclusion criteria are met is required.

Exclusion Criteria

Received endovascular treatment with clot engagement.
Patients who undergo groin puncture but clot engagement is not attempted due to spontaneous distal migration are permitted to be enrolled in the trial if all other eligibility criteria are met.
Patients who undergo groin puncture but clot is not engaged due to reasons other than spontaneous distal migration are NOT permitted.
Received or planned to receive intravenous thrombolysis.
Pre-stroke modified Rankin score \>2.
Previous treatment with TS23 or known previous allergy to antibody therapy.
Known pregnancy, women who are breastfeeding or plan to breastfeed within 3 months of receiving TS23 or have a positive urine or serum pregnancy test for women of childbearing potential.
Known previous stroke in the past 90 days.
Known previous intracranial hemorrhage, intracranial neoplasm, subarachnoid hemorrhage, or arterial venous malformation.
Known active diagnosis of intracranial neoplasm.
Clinical presentation suggestive of a subarachnoid hemorrhage, even if initial CT scan was normal.
Surgery or biopsy of parenchymal organ in the past 30 days.
Known trauma with internal injuries or persistent ulcerative wounds in the past 30 days.
Severe head trauma in the past 90 days.
Persistent systolic blood pressure \>180mmHg or diastolic blood pressure \>105mmHg despite best medical management.
Serious systemic hemorrhage in the past 30 days.
Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with International Normalized Ratio (INR) \>1.7.
Platelets \<100,000/mm3.
Hematocrit \<25 %.
Elevated aPTT above laboratory upper limit of normal.
Creatinine \> 4 mg/dl, or patients receiving renal dialysis, regardless of creatinine.
Received the following within the previous 24 hours:
If patient received unfractionated heparin within the last 24 hours, the patient must have an aPTT within normal range prior to enrollment.
Low molecular weight heparins such as Dalteparin, enoxaparin, tinzaparin in full dose within the previous 24 hours.
Received Factor Xa inhibitors (such as Fondaparinux, apixaban or rivaroxaban) within the past 48 hours.
Received direct thrombin inhibitors (e.g., argatroban, dabigatran, bivalirudin, desirudin, lepirudin) within 48 hours.
Received glycoprotein IIb/IIIa inhibitors within the past 14 days.
Known pre-existing neurological or psychiatric disease which would confound the neurological/functional evaluations.
Current participation in another research drug treatment protocol (i.e., participants could not start another experimental agent until after 90 days).
Concurrent acute myocardial infarction, pulmonary embolism, deep venous thrombosis or other thrombotic event that requires anticoagulation or anti-platelet treatment.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Birmingham?

Yes, this clinical trial (NCT05948566) has an active research site in Birmingham, AL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Ischemic Stroke Treatment Options in Birmingham, AL

If you're searching for ischemic stroke treatment options in Birmingham, AL, this clinical trial (NCT05948566) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Birmingham research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced ischemic stroke specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all ischemic stroke clinical trials near you to find additional studies recruiting in your area.

More Stroke Trials in Birmingham, AL

See all stroke clinical trials recruiting in Birmingham — not just this study.

Browse Stroke Trials in Birmingham →

Browse More Trials by Condition

Stroke TrialsHeart Attack TrialsInterstitial Cystitis TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Birmingham?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Birmingham, AL